IRVINE, CA--(Marketwired - February 19, 2014) - TRIMEDYNE, INC. (OTCQB: TMED) (OTCBB: TMED) today reported its financial results for the first quarter of its fiscal year.
Revenues for the quarter ended December 31, 2013, were $1,399,000, a 5.2% decrease from revenues of $1,475,000 for the prior year's quarter. The Company had a net loss of $259,000 or $0.014 per share for the current quarter, compared to a loss of $144,000 or $0.008 per share for the same quarter of the prior year, based on a weighted average of 18,395,960 shares outstanding.
Cash on hand increased by $27,000 to $1,599,000 during the quarter ended December 31, 2013.
Trimedyne manufactures proprietary Holmium lasers and fiber optic laser devices for vaporizing spinal disc tissue to treat herniated or ruptured discs, denervating spinal joints, fragmenting urinary stones, vaporizing prostate tissue to treat BPH and in a variety of other, minimally invasive procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. For product, press release, financial and other information, please visit Trimedyne's website, http://www.trimedyne.com.
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:
Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like "expect", "may", "could" and others. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's current Form 10-K Report and subsequently filed SEC reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.